177 related articles for article (PubMed ID: 35040786)
1. Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Kahraman R; Şahin A; Öztürk O; Çalhan T; Sayar S; Kanat E; Doğanay L; Özdil K
Turk J Gastroenterol; 2022 Jan; 33(1):35-43. PubMed ID: 35040786
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.
Yip TC; Lai JC; Yam TF; Tse YK; Hui VW; Lai MS; Chan HL; Wong VW; Wong GL
J Hepatol; 2024 Apr; 80(4):553-563. PubMed ID: 38101755
[TBL] [Abstract][Full Text] [Related]
3. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
Tonon M; Piano S; Romano A; Fasolato S; Stanco M; Pilutti C; Pontisso P; Mareso S; Gambino C; Sartori L; Angeli P
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):284-290. PubMed ID: 29309397
[TBL] [Abstract][Full Text] [Related]
5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
9. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
11. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
12. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?
Gill US; Zissimopoulos A; Al-Shamma S; Burke K; McPhail MJ; Barr DA; Kallis YN; Marley RT; Kooner P; Foster GR; Kennedy PT
J Infect Dis; 2015 Feb; 211(3):374-82. PubMed ID: 25156561
[TBL] [Abstract][Full Text] [Related]
13. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir.
Huang PY; Chiu SY; Chang KC; Tseng PL; Yen YH; Tsai MC; Wang JH; Kee KM; Chen CH; Hung CH; Chiu KW; Hu TH
Hepatol Int; 2021 Apr; 15(2):310-317. PubMed ID: 33907949
[TBL] [Abstract][Full Text] [Related]
14. Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?
Atalay R; Sayar S; Ayrancı FG; Çakmak Ş; Tanboğa İH; Doğanay L; Özdil K
Turk J Gastroenterol; 2022 Jul; 33(7):587-595. PubMed ID: 35879916
[TBL] [Abstract][Full Text] [Related]
15. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
16. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Yang X; Yan H; Zhang X; Qin X; Guo P
Int J Infect Dis; 2022 Nov; 124():133-142. PubMed ID: 36122671
[TBL] [Abstract][Full Text] [Related]
17. Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate.
Wen WH; Chen HL; Shih TT; Wu JF; Ni YH; Lee CN; Zhao LL; Lai MW; Mu SC; Tung YC; Hsu HY; Chang MH;
J Hepatol; 2020 Jun; 72(6):1082-1087. PubMed ID: 32044401
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]